Macrolide resistance in pneumococci—is it relevant?

Macrolide antibiotics are widely used for a range of indications, including pneumonia. Both high-level and low-level resistance to macrolides is increasing in pneumococci globally. Macrolide resistance in pneumococci is of limited clinical relevance where ß-lactams remain the mainstay of treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Allen C., Jenney, Adam W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471688/
https://www.ncbi.nlm.nih.gov/pubmed/28702289
http://dx.doi.org/10.1186/s41479-016-0010-1
_version_ 1783243996295856128
author Cheng, Allen C.
Jenney, Adam W. J.
author_facet Cheng, Allen C.
Jenney, Adam W. J.
author_sort Cheng, Allen C.
collection PubMed
description Macrolide antibiotics are widely used for a range of indications, including pneumonia. Both high-level and low-level resistance to macrolides is increasing in pneumococci globally. Macrolide resistance in pneumococci is of limited clinical relevance where ß-lactams remain the mainstay of treatment, such as for moderate/severe pneumonia; however, data suggest that macrolides may not be able to be relied on as monotherapy for serious pneumococcal infections.
format Online
Article
Text
id pubmed-5471688
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54716882017-07-12 Macrolide resistance in pneumococci—is it relevant? Cheng, Allen C. Jenney, Adam W. J. Pneumonia (Nathan) Commentary Macrolide antibiotics are widely used for a range of indications, including pneumonia. Both high-level and low-level resistance to macrolides is increasing in pneumococci globally. Macrolide resistance in pneumococci is of limited clinical relevance where ß-lactams remain the mainstay of treatment, such as for moderate/severe pneumonia; however, data suggest that macrolides may not be able to be relied on as monotherapy for serious pneumococcal infections. BioMed Central 2016-07-07 /pmc/articles/PMC5471688/ /pubmed/28702289 http://dx.doi.org/10.1186/s41479-016-0010-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Cheng, Allen C.
Jenney, Adam W. J.
Macrolide resistance in pneumococci—is it relevant?
title Macrolide resistance in pneumococci—is it relevant?
title_full Macrolide resistance in pneumococci—is it relevant?
title_fullStr Macrolide resistance in pneumococci—is it relevant?
title_full_unstemmed Macrolide resistance in pneumococci—is it relevant?
title_short Macrolide resistance in pneumococci—is it relevant?
title_sort macrolide resistance in pneumococci—is it relevant?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471688/
https://www.ncbi.nlm.nih.gov/pubmed/28702289
http://dx.doi.org/10.1186/s41479-016-0010-1
work_keys_str_mv AT chengallenc macrolideresistanceinpneumococciisitrelevant
AT jenneyadamwj macrolideresistanceinpneumococciisitrelevant

Ejemplares similares